Starting triple oral hypoglycemic agent therapy in poorly controlled type 2 diabetes is a suitable therapeutic strategy to lower HbA1c when insulin therapy is not desired-Reference-Cited by-同舟云学术

Starting triple oral hypoglycemic agent therapy in poorly controlled type 2 diabetes is a suitable therapeutic strategy to lower HbA1c when insulin therapy is not desired

Published:2021-06-29 Issue:1 Volume:7 Page:
ISSN:2379-4550
Container-title:Clinical Research In Practice: The Journal of Team Hippocrates
language:en
Short-container-title:Clin Res Pract

Author:

Darian Mara A¹

Affiliation:

1. Wayne State University School Of Medicine

Abstract

A clinical decision report using: Søfteland E, Meier JJ, Vangen B, Toorawa R, Maldonado-Lutomirsky M, Broedl UC. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial. Diabetes Care. 2016;40(2):201-209. https://doi.org/10.2337/dc16-1347 for a patient with uncontrolled type 2 diabetes on metformin and sitagliptin and hesitant to begin insulin therapy.

Publisher

Wayne State University Library System

Subject

General Environmental Science

Reference14 articles.

1. Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin

2. One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin

3. Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes

4. Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial

5. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes